GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (OTCPK:NICXF) » Definitions » Institutional Ownership

Nicox (NICXF) Institutional Ownership : 3.80% (As of Apr. 28, 2024)


View and export this data going back to . Start your Free Trial

What is Nicox Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nicox's institutional ownership is 3.80%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nicox's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nicox's Float Percentage Of Total Shares Outstanding is 0.00%.


Nicox Institutional Ownership Historical Data

The historical data trend for Nicox's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Institutional Ownership Chart

Nicox Historical Data

The historical data trend for Nicox can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 5.53 5.14 5.07 3.82 3.82 3.88 3.93 3.93 3.80 3.80

Nicox Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Nicox (NICXF) Business Description

Traded in Other Exchanges
Address
2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (NICXF) Headlines